Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

U.S. Court Rejects Allergan’s Attempt To Use Tribal Immunity To Shield Restasis Patents

By Catherine Sbeglia | July 23, 2018

In September 2017, Allergan agreed to pay the Saint Regis Mohawk Tribe of Upstate New York $15 million a year to take ownership of the company’s Restasis patents. As a sovereign entity, the tribe claimed immunity from civil patent challenges.

Following this move, Mylan NV, Teva Pharmaceutical Industries Ltd., and Akorn Inc all filed challenges against Allergan, who maintained tribal immunity. On Friday, however, a U.S. appeals court ruled that Allergan and St. Regis Mohawk Indian Tribe can’t use tribal sovereign immunity to shield patents on the dry-eye drug Restasis from challenges at the U.S. Patent and Trademark Office.

Restastis is the company’s second-best selling drug, second only to the company’s wrinkle treatment, Botox. Sales from the dry-eye drug make up more than 9 percent of the company’s total revenue, generating $1.5 billion in sales last year. That number, though, is anticipated to drop significantly if low-cost versions enter the market. 

Reviews of the challenges filed against Allergan will now proceed at the Patent Trial and Appeal Board in Alexandria, Virginia. To shield Restasis from generic competition before the patents’ 2024 expiration date, the company will need to win in both venues. 

(Source: Bloomberg)

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards